| Literature DB >> 31909382 |
Halil Buluc1, Arzu Yildirim Ar1, Guldem Turan1, Firdevs Karadogan2, Mehmet Akif Sargin3, Nur Akgun1.
Abstract
OBJECTIVE: Several methods are used to control the pain after cesarean operations. Recently, the transverse abdominis plane block (TAP) has been proposed to compensate for the problems developed by preexisting methods. In the present study, we compared the analgesic efficacy of the TAP block after caesarean section in a prospective, randomized, double-blinded controlled trial.Entities:
Keywords: Bupivacaine; cesarean section; post-operative pain; transverse abdominis plane block; ultrasound
Year: 2019 PMID: 31909382 PMCID: PMC6936937 DOI: 10.14744/nci.2018.97059
Source DB: PubMed Journal: North Clin Istanb ISSN: 2536-4553
FIGURE 1Ultrasound image during initial injection, image of the needle and the muscle layers.
Evaluation of the demographic characteristics between the groups
| TAP Group Median±SD | Control Group Median±SD | Total Median±SD | p | |
|---|---|---|---|---|
| Age (year) | 30.27±4.79 | 28.8±4.13 | 29.53±4.45 | [ |
| BMI (kg/m2) | 30.08±4.16 | 30.62±6.4 | 30.35±5.31 | [ |
| Operation time (min) | 50.2±11.72 | 38.0±10.82 | 44.1±12.7 | [ |
| ASA, n (%) | ||||
| 1 | 11 (73.3) | 12 (80) | 23 (76.7) | [ |
| 2 | 4 (26.7) | 3 (20) | 7 (23.3) | |
| Additional diseases n (%) | 4 (26.7) | 3 (20) | 7 (23.3) | [ |
Student’s t-Test;
Fisher’s Exact Test;
p<0.01; SD: Standard deviation.
Visual Analog Scale (VAS) Variation
| VAS | Group T Mean±SD (Median) | Group C Mean±SD (Median) | p |
|---|---|---|---|
| Postop 1st min | 2.27±0.88 (3) | 5.2±1.82 (6) | 0.001 |
| Postop 5th min | 2.27±0.88 (3) | 4.13±1.88 (3)‡ | 0.004 |
| Postop 15th min | 1.93±1.1 (2)† | 3.33±1.59 (3)‡ | 0.012 |
| Postop 30th min | 1.93±1.1 (2)† | 2.53±0.83 (3)‡ | 0.096 |
| Postop 1st hr | 1.8±1.01 (2)‡ | 2.07±1.44 (2)‡ | 0.829 |
| Postop 2nd hr | 1.4±1.18 (1)‡ | 1.4±0.91 (2)‡ | 0.914 |
| Postop 4th hr | 1.13±0.99 (1)‡ | 1.27±0.88 (1)‡ | 0.583 |
| Postop 6th hr | 1.13±1.13 (1)‡ | 1.07±0.7 (1)‡ | 0.983 |
| Postop 12th hr | 0.73±0.96 (0)‡ | 0.73±0.59 (1)‡ | 0.634 |
| Postop 24th hr | 0.47±0.64 (0)‡ | 0.6±0.51 (1)‡ | 0.396 |
Mann-Whitney U Test; †‡Wicoxon Sign Test;
p<0.05;
p<0.01; †when evaluating in-group p<0.05; ‡ when evaluating in-group p<0.01; SD: Standard deviation.
Verbal Descriptor Scale (VDS) Variation
| VDS | Group T Mean±SD (Median) | Group C Mean±SD (Median) | p |
|---|---|---|---|
| Postop 1st min | 1.33±0.49 (1) | 2.53±0.64 (3) | 0.001 |
| Postop 5th min | 1±0.38 (1)† | 2.33±0.72 (2) | 0.001 |
| Postop 15th min | 0.93±0.46 (1)† | 2.07±0.96 (2)† | 0.001 |
| Postop 30th min | 0.93±0.46 (1)† | 1.93±0.88 (2)† | 0.001 |
| Postop 1st hr | 0.93±0.46 (1)† | 1.4±0.74 (1)‡ | 0.047 |
| Postop 2nd hr | 0.8±0.56 (1)‡ | 1.13±0.64 (1)‡ | 0.140 |
| Postop 4th hr | 0.73±0.46 (1)‡ | 0.93±0.59 (1)‡ | 0.339 |
| Postop 6th hr | 0.73±0.59 (1)‡ | 0.8±0.56 (1)‡ | 0.732 |
| Postop 12th hr | 0.6±0.63 (1)‡ | 0.47±0.52 (0)‡ | 0.604 |
| Postop 24th hr | 0.27±0.46 (0)‡ | 0.4±0.51 (0)‡ | 0.446 |
Mann-Whitney U Test; †‡Wicoxon Sign Test;
p<0.05;
p<0.01; †when evaluating in-group p<0.05; ‡when evaluating in-group p<0.01; SD: Standard deviation.
FIGURE 2The meperidine dose variation between the groups.